US2020230162A1PendingUtilityA1

Nutritional formulations using human milk oligosaccharides for modulating inflammation

56
Assignee: ABBOTT LABPriority: Dec 20, 2012Filed: Apr 2, 2020Published: Jul 23, 2020
Est. expiryDec 20, 2032(~6.4 yrs left)· nominal 20-yr term from priority
Inventors:Geralyn O. Duska-McewenSarah S. ComstockSharon DonovanRachael BuckJoseph P. Schaller
A23V 2250/1614A23V 2250/154A23V 2250/702A23L 33/105A23V 2250/628A23L 21/00A23V 2250/5424A23L 33/15A61K 31/702A23V 2250/0612A23V 2250/7044A23L 33/22A23V 2250/706A61K 31/202A23V 2250/5036A23V 2250/1626A23L 33/10A23V 2250/712A23V 2250/5488A61P 11/00A23L 33/115A23L 33/125A23V 2250/28A23V 2250/1588A23V 2250/304A23V 2250/1608A23V 2250/032A23L 7/00A23V 2250/1642A23V 2250/72A23V 2250/7058A23V 2250/161A61K 45/06A23V 2250/7106A23V 2200/324A61P 31/00A23V 2250/1598A23V 2250/5108A23V 2250/7056A23L 33/21A23V 2250/1578A61P 31/12A23V 2250/708A23L 33/40A23L 33/12A23V 2250/16A61K 31/015A23V 2250/1612A61K 31/7028A23L 9/00A23V 2250/7046A23V 2002/00A23V 2250/1586A23L 29/30A23V 2250/5054A23V 2250/61A23V 2250/1592A23V 2250/54252A23V 2250/5114A23L 5/00A61K 9/0095A23V 2250/54246A61P 29/00A23V 2250/1842A23L 2/52A23V 2250/705
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is a nutritional composition for use in modulating or reducing inflammation in an adult or elderly individual in need thereof. In some aspects, the nutritional composition comprises a neutral human milk oligosaccharide.

Claims

exact text as granted — not AI-modified
1 .- 14 . (canceled) 
     
     
         15 . A nutritional composition for reducing inflammation in an adult or elderly individual in need thereof, the nutritional composition comprising at least one neutral human milk oligosaccharide in a concentration of from 0.001 mg/mL to 25 mg/mL, that reduces platelet-neutrophil complex formation. 
     
     
         16 . The nutritional composition according to  claim 15 , wherein the at least one neutral human milk oligosaccharide is selected from the group consisting of 2′-fucosyllactose and lacto-N-neotetraose (LNnT) and combinations thereof. 
     
     
         17 . The nutritional composition according to  claim 15 , wherein the at least one neutral human milk oligosaccharide is 2′-fucosyllactose, and wherein 2′-fucosyllactose is present in the nutritional composition in a concentration of from 0.001 mg/mL to 15 mg/mL. 
     
     
         18 . The nutritional composition according to  claim 15 , wherein the at least one neutral human milk oligosaccharide is 2′-fucosyllactose, and wherein 2′-fucosyllactose is present in the nutritional composition in a concentration of from 0.050 mg/mL to 10 mg/mL. 
     
     
         19 . The nutritional composition according to  claim 15 , wherein the at least one neutral human milk oligosaccharide is 2′-fucosyllactose, and wherein 2′-fucosyllactose is present in the nutritional composition in a concentration of from 0.1 mg/mL to 10 mg/mL. 
     
     
         20 . The nutritional composition according to  claim 15 , wherein the at least one neutral human milk oligosaccharide is lacto-N-neotetraose (LNnT), and wherein LNnT is present in the nutritional composition in a concentration of from 0.1 mg/mL to 5 mg/mL. 
     
     
         21 . The nutritional composition according to  claim 15 , wherein the nutritional composition additionally comprises 3-fucosyllactose, which is present in the nutritional composition in a concentration of from 0.001 mg/mL to 10 mg/mL. 
     
     
         22 . The nutritional composition according to  claim 15 , wherein the composition additionally comprises a long chain polyunsaturated fatty acid in a concentration that does not exceed 5% of total fat content in the nutritional composition. 
     
     
         23 . The nutritional composition according to  claim 15 , wherein the composition additionally comprises a carotenoid, in a concentration from 0.001 μg/mL to 10 μg/mL. 
     
     
         24 . The nutritional composition according to  claim 15 , wherein the composition additionally comprises an acidic human milk oligosaccharide in a concentration ranging from 0.001 mg/mL to 10 mg/mL. 
     
     
         25 . The nutritional composition according to  claim 15 , wherein the composition is a synthetic formula. 
     
     
         26 . The nutritional composition according to  claim 15 , wherein the inflammation is respiratory virus-induced inflammation. 
     
     
         27 . A nutritional composition for modulating inflammation in an adult or elderly individual in need thereof, the composition comprising a neutral human milk oligosaccharide in a concentration ranging from about 0.001 mg/mL to about 10 mg/mL, a long chain polyunsaturated fatty acid in a concentration that does not exceed about 5% of total fat content in the nutritional composition, and a carotenoid in a concentration from about 0.001 μg/mL to about 10 μg/mL. 
     
     
         28 . The nutritional composition according to  claim 27 , wherein the composition is a synthetic formula.

Join the waitlist — get patent alerts

Track US2020230162A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.